Zura Bio Ltd (ZURA) — SEC Filings
Zura Bio Ltd (ZURA) — 50 SEC filings. Latest: 8-K (May 7, 2026). Includes 36 8-K, 6 10-Q, 4 SC 13G/A.
View Zura Bio Ltd on SEC EDGAR
Overview
Zura Bio Ltd (ZURA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Zura Bio Ltd (ZURA) reported a net loss of $18.04 million for the three months ended September 30, 2025, a decrease from the $20.70 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $51.48 million, compared to $38.78 million in the pri
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 44 neutral, 2 mixed. The dominant filing sentiment for Zura Bio Ltd is neutral.
Filing Type Overview
Zura Bio Ltd (ZURA) has filed 36 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 4 SC 13G/A, 1 8-K/A with the SEC between May 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ZURA's 43 recent filings, 2 were flagged as high-risk, 22 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$18.04M |
| EPS | N/A |
| Debt-to-Equity | 0.02 |
| Cash Position | $139.02M |
| Operating Margin | N/A |
| Total Assets | $143.94M |
| Total Debt | $0.25M |
Key Executives
- Dr. Priya Kumar
- Mr. David Chen
- Dr. Jonathan Lim
- Dr. David Sidransky
- Mr. David E. Johnson
- Dr. Joshua Kazer
- Ms. Sarah K. Kelly
Industry Context
Zura Bio operates in the highly competitive clinical-stage biotechnology sector, focusing on immunology. The market for treatments for conditions like hidradenitis suppurativa and systemic sclerosis is growing, driven by unmet medical needs. However, it is characterized by significant R&D investment, long development cycles, and intense competition from both large pharmaceutical companies and smaller biotech firms.
Top Tags
biotech (11) · acquisition (10) · financials (7) · disclosure (5) · merger (5) · corporate-governance (4) · warrants (4) · operations (4) · corporate-action (4) · 8-K (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $18.04M | Decreased from $20.70M in Q3 2024, showing a slight improvement in quarterly performance. |
| Net Loss (9 Months 2025) | $51.48M | Increased from $38.78M in 9 months 2024, indicating a widening year-to-date loss. |
| R&D Expenses (Q3 2025) | $11.95M | Significantly increased from $6.03M in Q3 2024, driven by Phase 2 trial initiations. |
| Cash and Cash Equivalents | $139.02M | As of September 30, 2025, down from $176.50M at December 31, 2024, reflecting substantial cash burn. |
| Class A Ordinary Shares Outstanding | 65,023,308 | As of November 10, 2025, indicating potential for future dilution. |
| Expected Closing Quarter | Q4 2025 | Anticipated timeframe for the acquisition to be completed. |
| Net Loss (Q2 2025) | $15.993M | Increased from $10.329M in Q2 2024, a 54.8% increase. |
| Net Loss (YTD Q2 2025) | $33.435M | Increased from $18.076M in YTD Q2 2024, an 84.9% increase. |
| Research and Development Expenses (YTD Q2 2025) | $19.178M | Increased from $9.132M in YTD Q2 2024, reflecting increased clinical trial activity. |
| General and Administrative Expenses (YTD Q2 2025) | $18.138M | Increased from $11.006M in YTD Q2 2024. |
| Cash and Cash Equivalents (June 30, 2025) | $154.490M | Decreased from $176.498M at December 31, 2024. |
| Net Decrease in Cash (YTD Q2 2025) | $22.008M | Represents cash used in operations and investing activities. |
| Class A Ordinary Shares Outstanding (June 30, 2025) | 62,064,270 | Decreased from 65,297,530 at December 31, 2024, due to warrant exchanges. |
| Weighted-Average Class A Ordinary Shares (Q2 2025) | 94,289,954 | Used in computing net loss per share, up from 74,947,369 in Q2 2024. |
| SEC File Number | 001-40598 | Identifies the company's registration with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Zura Bio Ltd (ZURA)?
Zura Bio Ltd has 50 recent SEC filings from May 2024 to May 2026, including 36 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZURA filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 44 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Zura Bio Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zura Bio Ltd (ZURA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zura Bio Ltd?
Key financial highlights from Zura Bio Ltd's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ZURA?
The investment thesis for ZURA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zura Bio Ltd?
Key executives identified across Zura Bio Ltd's filings include Dr. Priya Kumar, Mr. David Chen, Dr. Jonathan Lim, Dr. David Sidransky, Mr. David E. Johnson and 2 others.
What are the main risk factors for Zura Bio Ltd stock?
Of ZURA's 43 assessed filings, 2 were flagged high-risk, 22 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Zura Bio Ltd?
Forward guidance and predictions for Zura Bio Ltd are extracted from SEC filings as they are enriched.